Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedOct 11, 2023fentaNYL in 0.9% sodium chlorideLack of assurance of sterility:Central Admixture Pharmacy Services Inc · D-0001-2024Class IIITerminatedOct 4, 2023Clearasil Rapid Rescue Deep Treatment PadsLabeling: Label Error on Declared Strength: The incorrect label on the back of the product packaging.RB Health (US) LLC · D-1179-2023Class IIITerminatedOct 4, 2023EligardSuperpotent Drug - Higher than expected levels of leuprolide acetate in the constituted product.Tolmar, Inc. · D-1178-2023Class IITerminatedOct 4, 2023Florbetaben F-18Lack of Assurance of Sterility: out-of-specification test results observed for Filter Integrity Test (FIT).Sofie Co dba Sofie · D-1177-2023Class IIOngoingSep 27, 2023Humanrace SuncareSubpotent Drug: Product does not contain SPF that is declared on the label.Humanrace · D-1176-2023Class IIOngoingSep 27, 2023Humanrace SuncareSubpotent Drug: Product does not contain SPF that is declared on the label.Humanrace · D-1175-2023Class IOngoingSep 27, 2023SANDIMMUNE Oral SolutionCrystallization: bottles of Sandimmune Oral Solution were determined to contain crystals.Novartis Pharmaceuticals Corp. · D-1174-2023Class IIITerminatedSep 27, 2023Kroger Mint Burst ANTISEPTIC MOUTH RINSE ANTIGINGIVITIS/ANTIPLAQUEIncorrect/Undeclared Excipients.Vi-Jon, LLC · D-1173-2023Class IIITerminatedSep 27, 2023Cequa (cyclosporine ophthalmic solution) 0.09%Subpotent: Out of Specification result observed for low assaySun Pharmaceutical Industries Inc · D-1172-2023Class IITerminatedSep 27, 2023Rasagiline Tablets 0.5mgFailed dissolution specifications - results obtained were below spec average.Aurobindo Pharma USA Inc. · D-1171-2023Class IICompletedSep 27, 2023BD ChloraPrep ClearStability data does not support expiry: Shelf-life of the impacted lots of BD ChloraPrep" Clear 1 mL Applicator cannot be substantiated beyond 12-months although labeled...CareFusion 213, LLC · D-1168-2023Class IIOngoingSep 27, 2023octiq Lubricating Eye DropsLack of Assurance of SterilityAmman Pharmaceutical Industries · D-1167-2023Class IIOngoingSep 27, 2023TRP Natural EyesLack of Assurance of SterilityAmman Pharmaceutical Industries · D-1166-2023Class IIOngoingSep 27, 2023TRP Natural EyesLack of Assurance of SterilityAmman Pharmaceutical Industries · D-1165-2023Class IIOngoingSep 27, 2023TRP Natural EyesLack of Assurance of SterilityAmman Pharmaceutical Industries · D-1164-2023Class IIOngoingSep 27, 2023TRP Natural EyesLack of Assurance of SterilityAmman Pharmaceutical Industries · D-1163-2023Class IIOngoingSep 27, 2023TRP Natural EyesLack of Assurance of SterilityAmman Pharmaceutical Industries · D-1162-2023Class IIOngoingSep 27, 2023TRP Natural EyesLack of Assurance of SterilityAmman Pharmaceutical Industries · D-1161-2023Class IIOngoingSep 27, 2023MAJOR LubriFresh P.M. Nighttime OintmentLack of Assurance of SterilityAmman Pharmaceutical Industries · D-1160-2023Class IIOngoingSep 27, 2023TRP Natural EyesLack of Assurance of SterilityAmman Pharmaceutical Industries · D-1159-2023Class IIOngoingSep 27, 2023TRP Natural EyesLack of Assurance of SterilityAmman Pharmaceutical Industries · D-1158-2023Class IIOngoingSep 27, 2023TRP Natural EyesLack of Assurance of SterilityAmman Pharmaceutical Industries · D-1157-2023Class IIOngoingSep 27, 2023TRP Natural EyesLack of Assurance of SterilityAmman Pharmaceutical Industries · D-1156-2023Class IIOngoingSep 27, 2023TRP Natural EyesLack of Assurance of SterilityAmman Pharmaceutical Industries · D-1155-2023Class IIOngoingSep 27, 2023TRP Natural EyesLack of Assurance of SterilityAmman Pharmaceutical Industries · D-1154-2023Class IIOngoingSep 27, 2023TRP Natural EyesLack of Assurance of SterilityAmman Pharmaceutical Industries · D-1153-2023Class IIOngoingSep 27, 2023TRP Natural EyesLack of Assurance of SterilityAmman Pharmaceutical Industries · D-1152-2023Class IIOngoingSep 27, 2023TRP Natural EyesLack of Assurance of SterilityAmman Pharmaceutical Industries · D-1151-2023Class ITerminatedSep 20, 2023WEFUN Capsules 825 mgMarketed Without an Approved NDA/ANDA: FDA analysis found the product to be tainted with sildenafil, an ingredient found in a FDA approved product for the treatment of...Hua Da Trading, Inc. dba Wefun Inc. · D-1180-2023Class IITerminatedSep 20, 2023Sucralfate Oral Suspension 1g per 10mLSuperpotent/Subpotent single ingredient Drug: Out of Specification Assay resultsVistaPharm LLC · D-1149-2023Class IITerminatedSep 20, 2023Pantoprazole Sodium for Injection 40mg per vialLack of Assurance of Sterility: Powder discoloration due to small crack in some vials.Be Pharmaceuticals AG · D-1148-2023Class IITerminatedSep 13, 2023Digoxin TabletsLabeling: Label Mix-Up- Bottles labeled as Digoxin Tablets, USP 0.125 mg contain Digoxin Tablets, USP 0.25mg and bottles labeled as Digoxin Tablets, USP 0.25mg contain...Marlex Pharmaceuticals, Inc. · D-1170-2023Class ITerminatedSep 13, 2023Digoxin TabletsLabeling: Label Mix-Up- Bottles labeled as Digoxin Tablets, USP 0.125 mg contain Digoxin Tablets, USP 0.25mg and bottles labeled as Digoxin Tablets, USP 0.25mg contain...Marlex Pharmaceuticals, Inc. · D-1169-2023Class IITerminatedSep 13, 2023Capsaicin Cream 0.025%Product mix-up: Cartons labeled Capsaicin Cream 0.025% may contain tubes of Sodium Fluoride 1.1% Prescription Dental ToothpasteAvkare LLC · D-1147-2023Class IITerminatedSep 13, 2023Sodium Fluoride 1.1%Cases of Sodium Fluoride 1.1% Prescription Dental Toothpaste may contain cartons labeled as Capsaicin Cream 0.025% but contain correctly labeled tubes of Sodium Fluoride...Avkare LLC · D-1146-2023Class IIITerminatedSep 13, 2023Fosfomycin Tromethamine Granules for Oral SolutionFailed Impurities/Degradation Specifications: Out-of-specification results observed for the organic impurities test at 6 months, RT Stability.Ascend Laboratories, LLC · D-1145-2023Class IIITerminatedSep 13, 2023Milrinone Lactate InjectionFailed Impurities/Degradation SpecificationsCaplin Steriles Limited · D-1144-2023Class IIITerminatedSep 13, 2023NexlizetFailed dissolution specifications: below specification results at stability 12-monthEsperion · D-1143-2023Class IOngoingSep 6, 2023Vegetal VigraMarketed Without an Approved NDA/ANDA: FDA analysis found the product to be tainted with sildenafil an ingredient found in a FDA approved product for the treatment of...Apg Seven, Inc · D-1150-2023Class IIICompletedSep 6, 2023Sabril (vigabatrin) for Oral SolutionCross contamination with other productsLundbeck LLC · D-1142-2023